Barclays Maintains Overweight on AbbVie, Raises Price Target to $325
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice TargetHot
Barclays analyst Emily Field maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $300 to $325.
Barclays analyst Emily Field maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $300 to $325.